Verition Fund Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Verition Fund Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-30,530	Closed	-$536K	–	2999
2021 Q3	$536K	Buy	+30,530	New	+$357K	﹤0.01%	1197
2021 Q1	–	Sell	-58,046	Closed	-$854K	–	1892
2020 Q4	$854K	Buy	+58,046	New	+$837K	0.01%	541

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Verition Fund Management's TRIL Position: Q4 2021 in Review

Verition Fund Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 30,530 shares — an estimated $536K sold.

Verition Fund Management first reported a position in TRIL in Q4 2020 and held it in 2 quarters. The position peaked at $854K in Q4 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Verition Fund Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Verition Fund Management sold 30,530 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $536K.
Verition Fund Management first reported a position in Trillium Therapeutics Inc. in Q4 2020 and held it in 2 quarters.
Verition Fund Management's Trillium Therapeutics Inc. position peaked at $854K in Q4 2020.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Verition Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.